# Carter BloodCare – FDA Inspection, Feb 14, 2020

Source: https://www.keypedia.com/records/fda_inspections/carter-bloodcare/5af8a736-088d-41ab-bd30-828bb9121553
Source feed: FDA_Inspections

> FDA inspection 1118763 of Carter BloodCare, February 14, 2020. Classification: No Action Indicated (NAI). 6 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1118763
- Company Name: Carter BloodCare
- Inspection Date: 2020-02-14
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1257153 - 2024-12-17
- FDA Inspection 1028502 - 2017-10-05
- FDA Inspection 945067 - 2015-10-06
- [FDA Inspection 871498 - 2014-03-26](https://www.keypedia.com/records/fda_inspections/carter-bloodcare/eb8323d0-1afe-46db-bd0c-2888ce1e116f)
- FDA Inspection 774031 - 2012-03-26

Company: https://www.keypedia.com/companies/carter-bloodcare/6cc5ca5f-4364-4676-b360-4a3f4f2a375c

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d